The local GI argument is the strongest case for capsules, but it is rarely explained correctly If BPC-157 is degraded locally in the gut lumen and acts on GI epithelial receptors before degradation, then high oral bioavailability is not required for a GI-local effect
This can lead to different kinds of anemia, fatigue, weakness, tingling in the fingers and toes, numbness, irregular heartbeat, mood swings, shortness of breath, very pale skin, memory loss, confusion, and more
not for diagnostic or therapeutic use
Cloudiness indicates one of three failures: bacterial contamination from non-sterile technique, air injection that denatured the peptide, or particulate matter from improper storage before reconstitution
We tell patients the best results are never noticeable as a surgical result, but rather look very natural